A triple dose of Novo Nordisk's GLP-1 agonist Wegovy has shown improved activity on weight loss in an obesity trial, as the drugmaker tries to fend off a marketplace challenge from Eli Lilly. A 7.2mg ...
Every time Sorin publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback